Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. (scientific article)

cites work (P2860)

Q47629452	"Tau immunotherapy: Hopes and hindrances".
Q33815578	A DNA damage-activated checkpoint kinase phosphorylates tau and enhances tau-induced neurodegeneration
Q37606284	Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Q54379908	Alterations of cyclin dependent kinase 5 expression and phosphorylation in amyloid precursor protein (APP)-transfected PC12 cells.
Q22251261	Alzheimer's disease as homeostatic responses to age-related myelin breakdown
Q39135430	An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease
Q33691128	Anesthesia induces phosphorylation of tau
Q36863032	Astroglial PTEN Loss Disrupts Neuronal Lamination by Dysregulating Radial Glia-guided Neuronal Migration
Q52690916	Biological function of Lemur tyrosine kinase 2 (LMTK2): implications in neurodegeneration.
Q34525891	CDK5 activator protein p25 preferentially binds and activates GSK3β
Q33988231	CDK5 is essential for soluble amyloid β-induced degradation of GKAP and remodeling of the synaptic actin cytoskeleton
Q38587949	Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses
Q35801936	Cdk5 protein inhibition and Aβ42 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease
Q38213140	Cdk5 regulates multiple cellular events in neural development, function and disease.
Q48883174	Cdk5-mediated phosphorylation of Axin directs axon formation during cerebral cortex development
Q47110701	Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy
Q37223230	Crosstalk between Cdk5 and GSK3beta: Implications for Alzheimer's Disease
Q37737296	Current therapeutic targets for the treatment of Alzheimer's disease
Q35772503	Cyclin-Dependent kinase 5 targeting prevents β-Amyloid aggregation involving glycogen synthase kinase 3β and phosphatases.
Q34113857	Cyclin-dependent kinase 5, a node protein in diminished tauopathy: a systems biology approach.
Q41599510	Cypermethrin Stimulates GSK3β-Dependent Aβ and p-tau Proteins and Cognitive Loss in Young Rats: Reduced HB-EGF Signaling and Downstream Neuroinflammation as Critical Regulators
Q26865654	Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets
Q37337494	Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells
Q28578526	Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain
Q35549137	Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits
Q38211426	Generation of the Cdk5 activator p25 is a memory mechanism that is affected in early Alzheimer's disease.
Q57833109	Global Approaches to Understanding Protein Kinase Functions
Q35492486	Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome
Q24657243	Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease
Q37984574	Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Q34805533	Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine
Q35071072	Inflammation induced by infection potentiates tau pathological features in transgenic mice
Q57461747	Inhibition of GSK-3 to induce cardiomyocyte proliferation-a recipe for in situ cardiac regeneration
Q64092809	Inhibition of SIRT2 by Targeting GSK3β-Mediated Phosphorylation Alleviates SIRT2 Toxicity in SH-SY5Y Cells
Q39178920	Mechanisms of Melatonin in Alleviating Alzheimer's Disease
Q37630546	Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease
Q30473576	Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta
Q34585571	Neuregulin1-β decreases IL-1β-induced neutrophil adhesion to human brain microvascular endothelial cells
Q37584417	Neurogenesis and Alzheimer's disease: at the crossroads
Q37981491	Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments
Q28300666	Neuroprotective Sirtuin ratio reversed by ApoE4
Q48413631	Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer's disease
Q30496792	Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions
Q37432069	Phosphorylation of neuronal survival factor MEF2D by glycogen synthase kinase 3beta in neuronal apoptosis
Q26860395	Physiological and pathological phosphorylation of tau by Cdk5
Q34014237	Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials
Q34200115	Prenatal alcohol exposure alters p35, CDK5 and GSK3β in the medial frontal cortex and hippocampus of adolescent mice
Q38214594	Protein phosphorylation in neurodegeneration: friend or foe?
Q99248419	RPS23RG1 modulates tau phosphorylation and axon outgrowth through regulating p35 proteasomal degradation
Q21129481	Recent developments of protein kinase inhibitors as potential AD therapeutics
Q37352348	Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model.
Q91712845	Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours
Q48672291	Safflower yellow ameliorates cognition deficits and reduces tau phosphorylation in APP/PS1 transgenic mice
Q28391148	Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition
Q37863144	Silencing of CDK5 as potential therapy for Alzheimer's disease
Q45971854	Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo.
Q37744878	Targeting tau protein in Alzheimer's disease
Q33980306	Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease
Q26739412	Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease
Q50632272	Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.
Q38715233	Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium
Q26864818	The Beta-amyloid protein of Alzheimer's disease: communication breakdown by modifying the neuronal cytoskeleton
Q36475393	The Ever-Changing Morphology of Hippocampal Granule Neurons in Physiology and Pathology
Q28392185	The role of Cdk5 in neuroendocrine thyroid cancer
Q37309824	The role of glycogen synthase kinase 3 in the early stages of Alzheimers' disease.
Q52722816	The role of septin 7 in physiology and pathological disease: A systematic review of current status.
Q81527536	Therapeutic strategies for Alzheimer's disease
Q42729005	Yeast as a model system to study tau biology.

P356	DOI	10.1523/JNEUROSCI.5245-07.2008
P932	PMC publication ID	6671193
P698	PubMed publication ID	18322105
P5875	ResearchGate publication ID	5530470

P2093	author name string	Li Liu
		Lili Wang
		Yi Wen
		Emmanuel Planel
		Karen E Duff
		Lit-Fui Lau
		Helen Y Figueroa
		Wai Haung Yu
		Mathieu Herman
P2860	cites work	Neuregulin-1 isoforms are differentially expressed in the intact and regenerating adult rat nervous system	Q48156753
		Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia.	Q48232865
		Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival	Q48271519
		Cdk5 is a key factor in tau aggregation and tangle formation in vivo	Q48300530
		p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway	Q48401217
		The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation	Q48486318
		A serine/threonine proline kinase activity is included in the tau protein kinase fraction forming a paired helical filament epitope	Q48687234
		ELISA method for measurement of amyloid-beta levels.	Q48832225
		Tissue processing prior to protein analysis and amyloid-beta quantitation.	Q48832234
		Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory.	Q50951137
		Neuregulin 1-erbB signaling is necessary for normal myelination and sensory function.	Q52022659
		p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo.	Q53594164
		Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.	Q54633263
		Schizophrenia genes - famine to feast	Q79912937
		Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia	Q24293245
		Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta	Q28139977
		GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides	Q28205921
		Control of peripheral nerve myelination by the beta-secretase BACE1	Q28264800
		Hyperphosphorylation of tau in PHF	Q28289907
		Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions	Q28375843
		Cdk5 is involved in neuregulin-induced AChR expression at the neuromuscular junction	Q28575776
		Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha	Q28616168
		Wnt signaling: a common theme in animal development	Q29547527
		The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3	Q29614380
		Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation.	Q33854281
		Phosphoinositide 3-kinase controls early and late events in mammalian cell division	Q34410971
		Tau neurofibrillary pathology and microtubule stability	Q35050284
		Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5	Q35084361
		The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator	Q35606861
		Cyclin-dependent kinase-5 in neurodegeneration.	Q35686119
		Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice	Q35791996
		MARKing tau for tangles and toxicity.	Q35902808
		Her-2 targeted therapy: beyond breast cancer and trastuzumab	Q36409209
		Neuregulin-1 and myelination	Q36416058
		Neuregulins and their receptors	Q36793133
		The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease	Q38611694
		Networking with proline-directed protein kinases implicated in tau phosphorylation	Q40416700
		Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event	Q40624453
		A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons	Q40901890
		PI3K: downstream AKTion blocks apoptosis	Q41351876
		Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.	Q41412181
		Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse	Q43664665
		Analysis of polymorphisms in AT-rich domains of neuregulin 1 gene in schizophrenia.	Q43853288
		Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation.	Q46097064
		Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia	Q46775363
		Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice.	Q48139851
P433	issue	10
P407	language of work or name	English	Q1860
P921	main subject	phosphorylation	Q242736
P304	page(s)	2624-2632
P577	publication date	2008-03-01
P1433	published in	Journal of Neuroscience	Q1709864
P1476	title	Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing
P478	volume	28

Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing.

scientific article

Reverse relations